Baidu
map

肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识

2017-01-30 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 临床肿瘤学杂志.2018,23(1):67-72.

重组改构人肿瘤坏死因子恶性胸腔积液腹腔积液

恶性胸、腹腔积液是晚期恶性肿瘤最常见的并发症之一，预后较差，临床上缺乏公认的标准治疗药物和方案。重组改构人肿瘤坏死因子( rmhTNF，天恩福) 为肿瘤生物免疫治疗药物，经过临床试验，2004 年获得国家食品药品监督管理总局( CFDA) 批准，作为国家一类生物制品在国内上市; 主要用于单药或联合化疗治疗复发难治的非小细胞肺癌( NSCLC)和非霍奇金淋巴瘤( NHL) 。注册临床研究和上市后IV

中文标题：

重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识

发布机构：

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会

发布日期：

2017-01-30

简要介绍：

恶性胸、腹腔积液是晚期恶性肿瘤最常见的并发症之一，预后较差，临床上缺乏公认的标准治疗药物和方案。重组改构人肿瘤坏死因子( rmhTNF，天恩福) 为肿瘤生物免疫治疗药物，经过临床试验，2004 年获得国家食品药品监督管理总局( CFDA) 批准，作为国家一类生物制品在国内上市; 主要用于单药或联合化疗治疗复发难治的非小细胞肺癌( NSCLC)和非霍奇金淋巴瘤( NHL) 。注册临床研究和上市后IV 期临床研究均表明，采用rmhTNF 腔内灌注治疗恶性胸、腹腔积液具有良效，且患者的安全性和耐受性较好。为了更好地指导临床上合理应用rmhTNF 治疗恶性胸、腹腔积液，中国临床肿瘤学会抗肿瘤药物安全管理专家委员会组织了相关领域的多学科专家学者，根据rmhTNF 上市前、后治疗恶性胸、腹腔积液的临床研究和真实世界的实践经验，参考国内、外有关文献，共同讨论，多次修改，形成本共识，以供临床医师用药参考。

 

拓展指南：与积液相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=899641c00156a911, title=重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识, enTitle=, guiderFrom=临床肿瘤学杂志.2018,23(1):67-72., authorId=null, author=, summary=恶性胸、腹腔积液是晚期恶性肿瘤最常见的并发症之一，预后较差，临床上缺乏公认的标准治疗药物和方案。重组改构人肿瘤坏死因子( rmhTNF，天恩福) 为肿瘤生物免疫治疗药物，经过临床试验，2004 年获得国家食品药品监督管理总局( CFDA) 批准，作为国家一类生物制品在国内上市; 主要用于单药或联合化疗治疗复发难治的非小细胞肺癌( NSCLC)和非霍奇金淋巴瘤( NHL) 。注册临床研究和上市后IV, cover=, journalId=null, articlesId=null, associationId=964, associationName=中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Jan 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>恶性胸、腹腔积液是晚期恶性肿瘤最常见的并发症之一，预后较差，临床上缺乏公认的标准治疗药物和方案。重组改构人肿瘤坏死因子( rmhTNF，天恩福) 为肿瘤生物免疫治疗药物，经过临床试验，2004 年获得国家食品药品监督管理总局( CFDA) 批准，作为国家一类生物制品在国内上市; 主要用于单药或联合化疗治疗复发难治的非小细胞肺癌( NSCLC)和非霍奇金淋巴瘤( NHL) 。注册临床研究和上市后IV 期临床研究均表明，采用rmhTNF 腔内灌注治疗恶性胸、腹腔积液具有良效，且患者的安全性和耐受性较好。为了更好地指导临床上合理应用rmhTNF 治疗恶性胸、腹腔积液，中国临床肿瘤学会抗肿瘤药物安全管理专家委员会组织了相关领域的多学科专家学者，根据rmhTNF 上市前、后治疗恶性胸、腹腔积液的临床研究和真实世界的实践经验，参考国内、外有关文献，共同讨论，多次修改，形成本共识，以供临床医师用药参考。 </P> <P> </P>拓展指南：<strong>与<font color=red>积液</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=c0b231c00105609a" title="2014 恶性胸腔积液诊断与治疗专家共识" target=_blank>2014 恶性胸腔积液诊断与治疗专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=bbb101c000e85886" title="2010 BTS 胸膜疾病指南：成人单侧胸腔积液的诊治" target=_blank>2010 BTS 胸膜疾病指南：成人单侧胸腔积液的诊治</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=de9c81c000e857b0" title="2010BTS 英国胸科学会胸膜疾病指南：恶性胸腔积液" target=_blank>2010BTS 英国胸科学会胸膜疾病指南：恶性胸腔积液</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E7%A7%AF%E6%B6%B2" target=_blank>有关积液更多指南</a></ul>, tagList=[TagDto(tagId=71280, tagName=重组改构人肿瘤坏死因子), TagDto(tagId=31458, tagName=恶性胸腔积液), TagDto(tagId=3575, tagName=腹腔积液)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7637, appHits=136, showAppHits=0, pcHits=4844, showPcHits=4267, likes=104, shares=10, comments=12, approvalStatus=1, publishedTime=Wed Mar 07 21:20:45 CST 2018, publishedTimeString=2017-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Mar 07 21:20:45 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:24:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识)])
重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=296105, encodeId=d87029610551, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Mar 14 08:33:23 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294801, encodeId=1407294801fd, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Mar 10 09:05:16 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294349, encodeId=106f29434979, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Mar 09 05:28:20 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294136, encodeId=1eb0294136f0, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Mar 08 08:53:54 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294126, encodeId=fe99294126e8, content=好好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Mar 08 08:02:05 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-14 Y—xianghai

    学习了新知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=296105, encodeId=d87029610551, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Mar 14 08:33:23 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294801, encodeId=1407294801fd, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Mar 10 09:05:16 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294349, encodeId=106f29434979, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Mar 09 05:28:20 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294136, encodeId=1eb0294136f0, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Mar 08 08:53:54 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294126, encodeId=fe99294126e8, content=好好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Mar 08 08:02:05 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-10 大爰

    学习了谢谢分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=296105, encodeId=d87029610551, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Mar 14 08:33:23 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294801, encodeId=1407294801fd, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Mar 10 09:05:16 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294349, encodeId=106f29434979, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Mar 09 05:28:20 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294136, encodeId=1eb0294136f0, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Mar 08 08:53:54 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294126, encodeId=fe99294126e8, content=好好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Mar 08 08:02:05 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-09 秀红

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=296105, encodeId=d87029610551, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Mar 14 08:33:23 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294801, encodeId=1407294801fd, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Mar 10 09:05:16 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294349, encodeId=106f29434979, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Mar 09 05:28:20 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294136, encodeId=1eb0294136f0, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Mar 08 08:53:54 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294126, encodeId=fe99294126e8, content=好好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Mar 08 08:02:05 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-08 龙胆草

    学习谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=296105, encodeId=d87029610551, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Mar 14 08:33:23 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294801, encodeId=1407294801fd, content=学习了谢谢分享!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Mar 10 09:05:16 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294349, encodeId=106f29434979, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Fri Mar 09 05:28:20 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294136, encodeId=1eb0294136f0, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Mar 08 08:53:54 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294126, encodeId=fe99294126e8, content=好好好学习天天向上, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Mar 08 08:02:05 CST 2018, time=2018-03-08, status=1, ipAttribution=)]
    2018-03-08 忠诚向上

    好好好学习天天向上

    0

以上为热门评论，梅斯医学App还有更多内容
Baidu
map
Baidu
map
Baidu
map